Neurocrine Biosciences | NBIX - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
Acadia Pharmaceuticals USD 243.27M 14.49M 2026-03
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
ALKERMES USD 331.33M 7M 2026-03
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amgen USD 6.89B 415M 2025-12
Biogen USD 1.82B 169.5M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Cytokinetics USD 19.2M 1.44M 2026-03
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Exelixis USD 590.86M 18.68M 2026-03
Gilead Sciences USD 5.52B 791M 2026-03
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Incyte USD 1.17B 217.51M 2026-03
Ionis Pharmaceuticals USD 243M 48M 2026-03
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Pfizer USD 11.04B 1.24B 2026-03
Prothena USD 51.08M 51.06M 2026-03
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Repligen USD 108.28M 4.45M 2026-03
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
Teva Pharmaceutical Industries USD 2.11B 547M 2026-03
Ultragenyx Pharmaceutical USD 106M 72M 2026-03
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03
Xoma 992K 846K 2024-06